FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
EAST RUTHERFORD, NJ, Nov. 08, 2017 -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has completed an expansion of cGMP small scale capacity at its Charles City, Iowa plant.
The project has seen the installation of two 500 gallon glass lined reactors and creates a third small scale work center, further increasing flexibility for customer projects.
“Small scale manufacturing has been identified as being a crucial area where capacity is at a premium within the industry, and this investment has been undertaken to increase our flexibility and reduce potential project bottle necks to benefit our customers,” commented Joe Nettleton, Vice President US Operations, Cambrex. “This continues Cambrex’s ongoing commitment to investing in small molecule manufacturing, ensuring that we can meet the challenges of customer project timelines, especially at the key development stages.”
This latest investment follows the completion of an expansion of large scale manufacturing capabilities and an announcement of the construction of a $24M, 4,500 sq. ft. highly potent API (HPAPI) manufacturing facility at Charles City, which is due to open in 2019.
Cambrex’s Charles City, Iowa facility is located on a 45-acre site and manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances. The facility was recently recognized by the Society of Chemical Manufacturers and Affiliates’ (SOCMA) ChemStewards® program, where it exceeded key performance requirements in federal environmental, health, safety and security compliance. As a result, the site qualified for the program’s highest ranking, the Excellence Tier.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com
Contact:
Alex Maw
Director, Marketing and Communications
Tel: +44 7803 443 155
Email: [email protected]
